Boĭko A N, Batysheva T T, Bykova O V, Davydovskaia M V, Demina T L, Lashch N Iu, Nankina I A, Ovcharov V V, Popova E V, Popova N F, Boĭko O V, Khachanova N V, Shchur S G, Gusev E I
Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(2 Pt 2):98-103.
The experience of the treatment of patients with remitting multiple sclerosis (MS) with intramuscular introduction of beta-interferon-1a (avonex) is presented. Seventeen children and adolescents, aged from 11 to 18 years, and 55 adults, aged over 55 years, were treated for at least one-year period. Results revealed a significant reduction of exacerbations in both groups (from 1.35 to 0.06 in average in adolescents and from 0.86 to 0.17 in adults). The changes were accompanied by the stabilization of MS severity index: EDSS scores have decreased in 23.6% of adults and in 17.6% of adolescents. In both groups, good tolerability of the treatment was noted. There was a low probability of side-effects with the exception of increased frequency of a flu-like syndrome (47% cases) in patients younger than 18 years that demands special attention from children neurologists. The high efficacy and good tolerability and safety profile of beta-interferon-1a give grounds for administering this drug to children and adolescents with MS.
本文介绍了对缓解型多发性硬化症（MS）患者进行肌肉注射β-干扰素-1a（阿沃尼克斯）的治疗经验。17名年龄在11至18岁的儿童和青少年以及55名年龄超过55岁的成年人接受了至少为期一年的治疗。结果显示两组的病情加重情况均显著减少（青少年平均从1.35降至0.06，成年人从0.86降至0.17）。这些变化伴随着MS严重程度指数的稳定：23.6%的成年人和17.6%的青少年的扩展残疾状态量表（EDSS）评分有所下降。两组均显示出对该治疗的良好耐受性。除了18岁以下患者中流感样综合征的发生率增加（47%的病例）外，副作用的发生概率较低，这需要儿童神经科医生特别关注。β-干扰素-1a的高疗效、良好耐受性和安全性为将该药物用于患有MS的儿童和青少年提供了依据。
